by TONY JIN
Captopril, a drug for hypertension and congestive heart failure first released by Bristol-Myers Squibb, is sold for ¥160 ($1 = ¥6.7) a pack of 12.5mg×100 in China, 23.2 times a similar Chinese-made product charging ¥6.9 (government set price).
Ciprofloxacin, an antibiotic first released by Bayer AG, is sold for ¥84.6 per 200mg/100ml injection, 18.8 times a Chinese-made equivalent product charging ¥4.5.
…
How come these drugs whose patents have expired, and more importantly, whose effect is no different compared to domestically made peers, still enjoy unreasonably high prices?
The China Perspective for more